Novo Nordisk : Le momentum du T1 2020 ne va pas durer
>Un T1 marqué par l’effet stockage - Suite à la conférence du management, nous confirmons que le T1 a été marqué par un stockage important des traitements à usage chronique du groupe (stockage notamment au niveau des patients) en anticipation des mesures de confinement un peu partout sur la planète. Cependant, COVID-19 aura un impact plus négatif sur Novo d’ici le T3 avec une inversion de l’effet stockage et l’impact économique de la crise aux USA.Semaglu...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.